



Albert Labs Welcomes Dr. Shabir Hasham to Board of Directors

October 17th 2023 - VANCOUVER, BRITISH COLUMBIA, – [Albert Labs International Corp.](#) (CSE: ABRT, the "Company" or "Albert Labs"), a fully-integrated biopharmaceutical drug discovery company bringing innovative medicines to patients with unmet mental health needs, is pleased to announce the appointment of Dr. Shabir Hasham to its Board of Directors. With an impressive 20 years of distinguished industry experience, Dr. Hasham brings a wealth of expertise to guide Albert Labs in its mission to revolutionize mental health solutions.

Regulatory Expertise: Dr. Hasham's exceptional career is marked by his proficiency in navigating regulatory bodies, including the FDA and MHRA, ensuring successful product launches and compliance. His regulatory acumen aligns seamlessly with Albert Labs' commitment to delivering innovative mental health solutions.

Neuroscience Franchise Expertise: As the former EU Medical Director for the Neuroscience Franchise at Novartis, Dr. Hasham played a pivotal role in advancing pharmaceutical solutions. His leadership is a testament to his deep understanding of the complexities involved in bringing transformative medicines to market.

Team Collaboration: Dr. Shabir Hasham's arrival marks a reunion with former team members, including Chief Medical Officer Dr. Malcolm Barrett Johnson and Chief Operations Officer Santoke Naal. His past collaborations with these key individuals, particularly during their tenure at Novartis, underscore Dr. Hasham's exceptional ability to drive successful outcomes in a collaborative environment.

Expertise in Pharma Leadership and Progressive Role: In addition to his 20 years of experience, Dr. Shabir Hasham will be progressively taking on an increased leadership role within Albert Labs. His informal leadership style, combined with strategic planning and operational excellence, aligns seamlessly with the company's vision for transformative solutions in mental health pharmaceuticals.

Biotechnology and Healthcare Investment Funds: Dr. Hasham possesses a unique proficiency in dealing with biotechnology and healthcare investment funds. His strategic insights have effectively guided investments, contributing to the success of various projects. Dr. Hasham's ability to communicate complex ideas in the right manner has been instrumental in securing support from investment entities, and ensuring alignment with organizational goals. Albert Labs looks forward to leveraging Dr. Shabir Hasham's multifaceted expertise as the company continues its pursuit of excellence in mental health pharmaceuticals.

Business of Albert Labs International Corp.

Albert Labs is a fully-integrated biopharmaceutical drug discovery company bringing innovative medicines to patients with unmet mental health needs. Its team of experts leverage advanced culture technology and natural extraction, coupled with a comprehensive regulatory approach, to accelerate the development of mental health drugs, for which patient needs are both urgent and unmet. Albert Labs looks to develop solutions through an approved, fast-track clinical pathway focusing on Real World Evidence (RWE). RWE studies are a recognised clinical pathway, heavily used in oncology and recently, in the successful development of COVID-19 vaccines.

Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to its treatment. Albert Labs' first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide.

The company's goal is to deliver effective medicines to those who suffer with their mental health in the shortest possible time without compromising safety and/or quality, while also providing significant returns to shareholders.

Albert Labs (CSE: ABRT) (FSE: VB50) is publicly [listed on the Canadian Securities Exchange \(CSE\)](#).

You can find more details about Albert Labs on our website [here](#).

ON BEHALF OF THE BOARD OF DIRECTORS

Albert Labs International Corp.

Chand Jagpal

Chief Financial Officer

For further information please contact:

Email: press@albertlabs.com

Website: <https://albertlabs.com/>

Tel: +1 778-819-0740

Tel: +44 1625 324 960

Cautionary Statement

This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward-looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate.

The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements.

Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward-looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities laws.